Overview: Gastrin Secretin Stimulation Panel
Introduction: The Gastrin Secretin Stimulation Panel is a diagnostic tool designed to assess gastrin response using serum samples. In India, gastrinoma (Zollinger-Ellison syndrome) is rare but underdiagnosed (~1 in 1,000,000), causing refractory peptic ulcers, diarrhea, and severe acid hypersecretion; secretin stimulation test distinguishes gastrinoma (paradoxical rise) from other hypergastrinemia causes. High morbidity from under-testing in rural/low-SES patients with recurrent ulcers, limited endocrinology labs, delayed proton pump inhibitor escalation or surgery leading to complications (perforation, bleeding). Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs immunoassay for basal and post-secretin gastrin levels (multiple time points) over 1-2 days with high specificity, valuable for confirming gastrinoma in patients with ulcers and hypergastrinemia. This diagnostic falls under hormonal screening and targets refractory ulcer or MEN1 patients, addressing accurate detection to guide somatostatin analogs or surgical resection. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing ulcer-related mortality. Its serum-based approach ensures reliable gastrin dynamics.
Other Names: Gastrin Stim Pnl.
FDA Status: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.
Historical Milestone: Secretin test standard; in India, used in ulcer clinics.
Purpose: The test assesses 7 parameters including basal gastrin to guide gastrinoma evaluation, detect paradoxical rise, inform therapy.
Test Parameters: 1. Basal Gastrin, 2â€"7. Post-Secretin Gastrin Levels (6 Time Points).
Pretest Condition: No fasting required; patients should have refractory ulcers or hypergastrinemia.
Specimen: 3 mL serum in 1 SST (multiple draws), transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on ulcer history, diarrhea, MEN1 family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated gastrinoma including ulcers, benefits of diagnosis, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret gastrin dynamics within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or PPI use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Paradoxical rise post-secretin confirms gastrinoma, necessitating specialist input. No rise suggests other causes.
Specialist Consultation: Endocrinologists or gastroenterologists should be consulted for management.
Additional Supporting Tests: Chromogranin A, endoscopy for confirmation.
Test Limitations: Requires secretin injection; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Gastrinoma Studies India 2023.
